货号:A843943
同义名:
α-亚麻酸
/ Octadecatrienoic acid (all cis-9,12,15); alpha-Linolenic acid
α-Linolenic acid是一种必需脂肪酸,通过调节 PI3K/Akt 信号通路影响血栓形成,具有抗心律失常和抗炎作用。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | α-Linolenic acid (ALA), isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer. α-Linolenic acid (50, 100, 250 mg/kg; for 10 days) can completely inhibit collagen- and adrenaline-induced thrombosis in mice at 250 mg/kg. α-Linolenic acid (35, 70, 175 mg/kg) suppresses A-V thrombus formation in rats (weighing at 250 ~ 300 g). α-Linolenic acid (70 or 175 mg/kg) inhibits collagen stimulated platelet aggregation in rats[3]. ALA but not LA supplementation alleviated systolic blood pressure elevation and improved ACh-induced, endothelium-dependent vasodilation in both spontaneously hypertensive rats (SHRs) and AngII-induced hypertensive mice. In primary cultured endothelial cells, ALA treatment directly inhibited SIRT3 reduction, SOD2 hyperacetylation, mitochondrial ROS overproduction and alleviated autophagic flux impairment induced by AngII plus TNFα treatment[4]. Consumption of vegetable oils rich in alpha-linolenic acid could confer important cardiovascular protection[5]. α-linolenic acid prevents ER stress-mediated apoptosis of stearic acid lipotoxicity on primary rat hepatocytes might become a target to develop new antiapoptotic compounds in nonalcoholic fatty liver disease[6]. ALA also as a potential nutraceutical to protect the brain from stroke, characterized by its pleiotropic effects in neuroprotection, vasodilation of brain arteries, and neuroplasticity[7]. |
| Concentration | Treated Time | Description | References | |
| Human aortic endothelial cells (HAEC) | 25 µM | 24 hours | ALA treatment directly inhibited SIRT3 reduction, SOD2 hyperacetylation, mitochondrial ROS overproduction, and alleviated autophagic flux impairment induced by AngII plus TNFα treatment. These beneficial effects were completely blocked by silencing SIRT3. | Cell Death Dis. 2020 Feb 3;11(2):83 |
| GNM cells | 0, 25, 50, 100, 200, 400, 600, 800 µM | 24 hours | ALA significantly decreased the cell viability of GNM cells, with a survival rate of 79.1% at a dose of 400 μM of ALA, and a survival rate of approximately 5% at 800 μM of ALA. | Nutrients. 2023 Dec 1;15(23):4992 |
| SAS cells | 0, 25, 50, 100, 200, 400, 600, 800 µM | 24 hours | ALA significantly reduced the cell viability of SAS cells, with a survival rate of 67.9% at a dose of 200 μM of ALA, while at 600 μM of ALA, the survival rate was only about 3.7%. | Nutrients. 2023 Dec 1;15(23):4992 |
| U2OS cells | 0, 10, 20, 30, 40, 60, 80, 100, 150, 200 µM | 24 hours | To assess the effect of α-linolenic acid on the viability of U2OS cells, results showed that α-linolenic acid inhibited cell proliferation in a dose-dependent manner with an IC50 value of 49.8 ± 0.50 μM. | Molecules. 2022 Apr 24;27(9):2741 |
| 143B cells | 0, 10, 20, 30, 40, 60, 80, 100, 150, 200 µM | 24 hours | To assess the effect of α-linolenic acid on the viability of 143B cells, results showed that α-linolenic acid inhibited cell proliferation in a dose-dependent manner with an IC50 value of 56.93 ± 0.23 μM. | Molecules. 2022 Apr 24;27(9):2741 |
| MG63 cells | 0, 10, 20, 30, 40, 60, 80, 100, 150, 200 µM | 24 hours | To assess the effect of α-linolenic acid on the viability of MG63 cells, results showed that α-linolenic acid inhibited cell proliferation in a dose-dependent manner with an IC50 value of 51.69 ± 0.14 μM. | Molecules. 2022 Apr 24;27(9):2741 |
| T cells | 10 µM | 3 weeks | The infiltration of T cells into the epidermis was reduced when ALA was added to the culture medium, and significant decreases in the levels of inflammatory cytokines and chemokines such as CXCL1, interleukin-6 (IL-6) and interleukin-8 (IL-8) were consequently measured in psoriatic substitutes supplemented with this n-3 PUFA. | Cells. 2022 Apr 30;11(9):1513 |
| Keratinocytes | 10 µM | 3 weeks | ALA supplementation regulated the hyperproliferation and abnormal cell differentiation of psoriatic keratinocytes stimulated by T cells. Additionally, the exogenous ALA was correctly incorporated into the phospholipids of keratinocytes, which resulted in increased levels of ALA, eicosapentaenoic acid (EPA) and n-3 docosapentaenoic acid (n-3 DPA). | Cells. 2022 Apr 30;11(9):1513 |
| Administration | Dosage | Frequency | Description | References | ||
| Spontaneously hypertensive rats (SHRs) and AngII-induced hypertensive mice | Spontaneously hypertensive rat model and AngII-induced hypertensive mouse model | Dietary supplementation | 10% flaxseed oil (ALA-supplemented diet) | Continued for 8 weeks (SHRs) or 4 weeks (AngII-induced hypertensive mice) | ALA supplementation alleviated systolic blood pressure elevation and improved ACh-induced, endothelium-dependent vasodilation in both SHRs and AngII-induced hypertensive mice. It also restored vascular SIRT3 expression, reduced SOD2 hyperacetylation, and mitochondrial ROS overproduction. | Cell Death Dis. 2020 Feb 3;11(2):83 |
| BALB/c nude mice | HepG2 and MCF-7/ADR cell xenograft models | Intravenous injection | 40 mg/kg ALA-PTX | Every 3 days for 4 times | Evaluate in vivo antitumor activity of ALA-PTX NPs, results showed significant tumor growth inhibition | Int J Nanomedicine. 2021 Oct 27;16:7269-7281 |
| BALB/c mice | OVA-induced allergic rhinitis mouse model | Intragastric administration | 500 and 2000 mg/kg | Once daily for 14 days | ALA significantly alleviated nasal symptoms, reduced OVA-sIgE levels in serum, relieved histopathological injuries in the nasal mucosa, and downregulated mRNA expression levels of IL-6 and IL-1β. ALA also significantly moderated the imbalance of Th1/Th2 cells, increased mRNA expression levels of T-bet and STAT1, and reduced GATA3 and STAT6. | Molecules. 2022 Sep 11;27(18):5893 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00892684 | Allergies | Not Applicable | Unknown | September 2011 | Sweden ... 展开 >> University Hospital Linkoeping, Sweden, 58185 收起 << |
| NCT01943409 | Obstruction C... 展开 >>ancer Ileus Malnutrition Surgery 收起 << | Phase 4 | Recruiting | June 2019 | Canada, Ontario ... 展开 >> University Health Network Recruiting Toronto, Ontario, Canada, M5G 2C4 Contact: Sultan Alenezi, MScAHN +1-416-340-4413 sultan.alenezi@uhnresearch.ca Contact: Monica L Ponta, MD +1-416-340-4413 monica.ponta@uhnresearch.ca Principal Investigator: Johane P Allard, MD 收起 << |
| NCT02590848 | Vitamin/Nutritional Deficiency... 展开 >> Neurobehavioral Manifestations 收起 << | Not Applicable | Active, not recruiting | January 2019 | Spain ... 展开 >> Fundació Centre de Recerca en Epidemiologia Ambiental Barcelona, Spain, 08003 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.59mL 0.72mL 0.36mL |
17.96mL 3.59mL 1.80mL |
35.92mL 7.18mL 3.59mL |
|
| CAS号 | 463-40-1 |
| 分子式 | C18H30O2 |
| 分子量 | 278.43 |
| SMILES Code | CC/C=C\C/C=C\C/C=C\CCCCCCCC(O)=O |
| MDL No. | MFCD00065720 |
| 别名 | α-亚麻酸 ;Octadecatrienoic acid (all cis-9,12,15); alpha-Linolenic acid; DPN63401; C18:3 (all cis-9,12,15) Fatty acid |
| 运输 | 蓝冰 |
| InChI Key | DTOSIQBPPRVQHS-PDBXOOCHSA-N |
| Pubchem ID | 5280934 |
| 存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 |
| 溶解方案 |
DMSO: 105 mg/mL(377.12 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 100 mg/mL(359.16 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1